CU24111B1 - Polipéptidos que se enlazan a cxcr2 - Google Patents

Polipéptidos que se enlazan a cxcr2

Info

Publication number
CU24111B1
CU24111B1 CU20130066A CU20130066A CU24111B1 CU 24111 B1 CU24111 B1 CU 24111B1 CU 20130066 A CU20130066 A CU 20130066A CU 20130066 A CU20130066 A CU 20130066A CU 24111 B1 CU24111 B1 CU 24111B1
Authority
CU
Cuba
Prior art keywords
cxcr2
polypeptides
link
Prior art date
Application number
CU20130066A
Other languages
English (en)
Other versions
CU20130066A7 (es
Inventor
Michelle Bradley
Zarin Brown
Steve John Charlton
Karen Cromie
Bruno Dombrecht
Soren Steffensen
Heeke Gino Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20130066A7 publication Critical patent/CU20130066A7/es
Publication of CU24111B1 publication Critical patent/CU24111B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CU20130066A 2010-11-08 2011-11-07 Polipéptidos que se enlazan a cxcr2 CU24111B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41108310P 2010-11-08 2010-11-08
PCT/EP2011/069571 WO2012062713A1 (en) 2010-11-08 2011-11-07 Cxcr2 binding polypeptides

Publications (2)

Publication Number Publication Date
CU20130066A7 CU20130066A7 (es) 2013-09-27
CU24111B1 true CU24111B1 (es) 2015-08-27

Family

ID=45001722

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20130066A CU24111B1 (es) 2010-11-08 2011-11-07 Polipéptidos que se enlazan a cxcr2

Country Status (28)

Country Link
US (3) US8591896B2 (es)
EP (3) EP2638068B1 (es)
JP (2) JP5933573B2 (es)
KR (2) KR101650995B1 (es)
CN (1) CN103328512B (es)
AR (1) AR083784A1 (es)
AU (4) AU2011328246B2 (es)
BR (1) BR112013011003B1 (es)
CA (2) CA3239880A1 (es)
CL (1) CL2013001168A1 (es)
CO (1) CO6761351A2 (es)
CR (1) CR20130202A (es)
CU (1) CU24111B1 (es)
EA (2) EA037063B1 (es)
ES (2) ES2723775T3 (es)
GT (1) GT201300113A (es)
IL (1) IL225897B (es)
MA (1) MA34711B1 (es)
MX (2) MX343085B (es)
NZ (1) NZ610075A (es)
PE (1) PE20140772A1 (es)
PH (1) PH12013500910A1 (es)
PY (1) PY1147875A (es)
SG (1) SG189981A1 (es)
TW (2) TWI619730B (es)
UA (1) UA115027C2 (es)
UY (1) UY33714A (es)
WO (1) WO2012062713A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2986642A1 (en) * 2013-04-17 2016-02-24 MorphoSys AG Antibodies targeting specifically human cxcr2
CN103396482B (zh) * 2013-05-17 2016-08-10 东南大学 一种前白蛋白纳米抗体、其编码序列及应用
EP3066120B1 (en) 2013-11-04 2018-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Synthetic single domain antibody
WO2015189162A1 (en) * 2014-06-09 2015-12-17 Theranyx Single-domain antibodies directed against a cys-loop receptor and methods for obtaining them
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
IL309890A (en) 2017-01-30 2024-03-01 Alexion Pharma Inc Monovalent anti-properdin antibodies and antibody fragments
CN110637034B (zh) * 2017-02-27 2023-10-10 莫纳什大学 Cxcr2抗体及其用途
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210041586A (ko) * 2018-08-01 2021-04-15 세파론, 인코포레이티드 항-cxcr2 항체 및 이의 용도
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
WO2021022249A1 (en) * 2019-08-01 2021-02-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
US20220332835A1 (en) * 2019-09-04 2022-10-20 Shanghaitech University Anti-cxcr2 antibodies and uses thereof
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2024039920A1 (en) * 2022-08-15 2024-02-22 Mbrace Therapeutics, Inc. Cell-free methods of producing antibodies to intracellular targets
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
EP4665755A1 (en) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2025011508A1 (zh) * 2023-07-07 2025-01-16 深圳先进技术研究院 降低肿瘤内中性粒细胞水平的抗肿瘤细菌
CN118994362B (zh) * 2024-08-06 2025-05-23 重庆医药高等专科学校 一种cxcr-2突变体及其制备方法和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
ES2149772T5 (es) 1991-03-29 2008-02-16 Genentech, Inc. Receptores humanos pf4a y su utilizacion.
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5374506A (en) 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor
ATE348175T1 (de) 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH08511160A (ja) 1993-06-09 1996-11-26 ユニリーバー・ナームローゼ・ベンノートシャープ 形質転換真カビによってＳｃＦｖフラグメントを含んでなる融合タンパク質を生産する方法
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
US6448379B1 (en) 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1998022141A2 (en) 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
AU3295299A (en) 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
ATE422545T1 (de) 1999-06-18 2009-02-15 Cv Therapeutics Inc Regulierung mittels atp binding cassette transporter proteins abc1
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US20030186889A1 (en) * 2000-03-31 2003-10-02 Wolf-Georg Forssmann Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
JP2004528031A (ja) 2001-03-14 2004-09-16 セントカー・インコーポレーテツド 慢性閉塞性肺疾患関連の免疫グロブリン由来タンパク質、組成物、方法および用途
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US20030064053A1 (en) 2001-08-31 2003-04-03 Shengjiang Liu Multivalent protein conjugate with multiple ligand-binding domains of receptors
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
US20060263774A1 (en) 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
ES2373947T3 (es) 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
ATE554390T1 (de) 2003-08-20 2012-05-15 Ucb Pharma Sa Verfahren zur gewinnung von antikörpern
WO2005103702A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
EP4353819A3 (en) 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Binding molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
NO322440B1 (no) 2004-10-19 2006-10-09 Per-Yngve Monsen Fremgangsmate og datasystem for ervervelse av kunder
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
RU2464276C2 (ru) * 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
EP1910828A4 (en) 2005-07-01 2012-03-14 Univ St Louis PHOSPHOSPECTIVE CHEMOKIN RECEPTOR ANTIBODIES
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
CN101070346A (zh) * 2006-05-08 2007-11-14 陈正贤 一种制备双功能抗体的方法
WO2008000279A1 (en) 2006-06-26 2008-01-03 Aida Centre, S.L. Blister package integrating rfid based tags
EP2046383B1 (en) 2006-07-04 2014-11-19 Genmab A/S Cd20 binding molecules for the treatment of copd
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008028044A2 (en) 2006-08-30 2008-03-06 Centocor, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
AU2007306340A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CN101932593B (zh) 2008-01-29 2014-08-20 埃博灵克斯股份有限公司 稳定蛋白和多肽的方法
NL2001374C2 (nl) 2008-03-13 2009-09-15 Securo B V Werkwijze voor het machinaal vervaardigen van een samenstel van een eerste flexibel vel en een tweede flexibel vel.
AU2009248049B2 (en) * 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DK2370465T3 (da) * 2008-12-19 2019-05-06 Ablynx Nv Genetisk immunisering til fremstilling af immunoglobuliner mod celleassocierede antigener, såsom p2x7, cxcr7 eller cxcr4
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド

Also Published As

Publication number Publication date
IL225897B (en) 2019-03-31
CA2817132C (en) 2025-11-04
BR112013011003A2 (pt) 2016-08-23
JP2016174611A (ja) 2016-10-06
KR20130108414A (ko) 2013-10-02
EP3578568A2 (en) 2019-12-11
EP3575321A1 (en) 2019-12-04
BR112013011003B1 (pt) 2021-12-07
AR083784A1 (es) 2013-03-20
MX343085B (es) 2016-10-24
MX2022013520A (es) 2022-11-16
KR20150051245A (ko) 2015-05-11
US10174118B2 (en) 2019-01-08
AU2011328246B2 (en) 2016-06-30
US8591896B2 (en) 2013-11-26
UY33714A (es) 2012-06-29
US9127067B2 (en) 2015-09-08
ES2970234T3 (es) 2024-05-27
PE20140772A1 (es) 2014-07-03
AU2020217351A1 (en) 2020-09-03
SG189981A1 (en) 2013-06-28
EA037063B1 (ru) 2021-02-01
EP3575321B1 (en) 2023-07-26
TW201736401A (zh) 2017-10-16
WO2012062713A1 (en) 2012-05-18
AU2018275016A1 (en) 2019-01-03
EP2638068A1 (en) 2013-09-18
AU2016234907A1 (en) 2016-10-20
EP3578568A3 (en) 2020-01-08
EA201390666A1 (ru) 2013-11-29
KR101650995B1 (ko) 2016-08-25
JP5933573B2 (ja) 2016-06-15
EP2638068B1 (en) 2018-12-26
GT201300113A (es) 2015-06-02
CO6761351A2 (es) 2013-09-30
EA202092589A2 (ru) 2021-03-31
US20170101476A1 (en) 2017-04-13
CL2013001168A1 (es) 2014-04-04
AU2018275016B2 (en) 2020-07-09
PH12013500910A1 (en) 2022-10-24
UA115027C2 (uk) 2017-09-11
ES2723775T3 (es) 2019-09-02
MA34711B1 (fr) 2013-12-03
CA2817132A1 (en) 2012-05-18
KR101832040B1 (ko) 2018-04-04
CN103328512B (zh) 2017-04-05
CR20130202A (es) 2013-06-28
US20140050736A1 (en) 2014-02-20
AU2020217351B2 (en) 2023-08-03
TWI619811B (zh) 2018-04-01
CU20130066A7 (es) 2013-09-27
EA202092589A3 (ru) 2021-06-30
IL225897A0 (en) 2013-06-27
JP6294382B2 (ja) 2018-03-14
NZ610075A (en) 2015-03-27
TW201233795A (en) 2012-08-16
JP2013545456A (ja) 2013-12-26
MX2013005186A (es) 2013-07-03
TWI619730B (zh) 2018-04-01
PY1147875A (es) 2015-08-03
AU2011328246A1 (en) 2013-05-23
US20120183549A1 (en) 2012-07-19
CA3239880A1 (en) 2012-05-18
CN103328512A (zh) 2013-09-25

Similar Documents

Publication Publication Date Title
CU24111B1 (es) Polipéptidos que se enlazan a cxcr2
DK2470243T3 (da) Samlesæt til fremstilling af en fyldt sprøjte
UY33171A (es) Plantas tolerantes a herbicidas
BRDI7004545S (pt) Configuração aplicada a um calçado
LT3540066T (lt) Pelė su bendra lengvąja grandine
DK3104003T3 (da) Nacellekonstruktion til en vindmølle
FR2950109B1 (fr) Turbomoteur a arbres paralleles
DK2683645T3 (da) Udligger til en lastekran
IT1403452B1 (it) Ingranaggio ad innesto a denti.
BR302012005315S1 (pt) Configuracao aplicada a uma torneira
DK2429882T3 (da) Forbindelsesanordning
BR112013010837A2 (pt) aperfeiçoamentos relativos a embalagens
BRDI7102414S (pt) Configuração aplicada a regulador de fluxo
DK2629865T3 (da) Legetøjsbyggesæt
DK2336623T3 (da) Fitting til et rør
BR302012005247S1 (pt) Configuração aplicada a uma torneira
PL2651915T3 (pl) Ciągły związek arycykliczny
BR302012005278S1 (pt) Configuração aplicada a uma torneira
DK2629863T3 (da) Legetøjsbyggesæt
BRDI7103354S (pt) Configuração aplicada a um recipiente
BR302012005246S1 (pt) Configuração aplicada a uma torneira
FI20125384L (fi) Juotosliitoksella varustettu järjestelmä
DE112011103890A5 (de) Verbindungsanordnung
FR2947288B1 (fr) Spatule a lisser
BR112013015335A2 (pt) plantas transgências resistentes a nematoides

Legal Events

Date Code Title Description
FG Grant of patent